Limits...
Highly expressed ribosomal protein L34 indicates poor prognosis in osteosarcoma and its knockdown suppresses osteosarcoma proliferation probably through translational control

View Article: PubMed Central - PubMed

ABSTRACT

Osteosarcoma has devastating health implications on children and adolescents. However, due to its low incidence and high tumor heterogeneity, it is hard to achieve any further improvements in therapy and overall survival. Ribosomal protein L34 (RPL34) has been increasingly recognized to promote the proliferation of malignant cells, but its role in osteosarcoma has not been investigated. In this study, real-time quantitative PCR (RT-qPCR) and immunohistochemistry revealed that RPL34 was highly expressed in osteosarcoma tissues when compared to adjacent tissues and normal bone tissues. Survival analysis showed that high expression of RPL34 predicted a poor prognosis for osteosarcoma patients. Knockdown of RPL34 in Saos-2 cells via lentivirus-mediated small interfering RNA (siRNA) significantly inhibited cell proliferation, induced cell apoptosis and G2/M phase arrest. Moreover, screening of transcription factors using University of California Santa Cruz (UCSC) Genome Browser, protein-protein interaction (PPI) network analysis, Gene Ontology (GO) and pathway enrichment analysis revealed that MYC participates in the transcriptional regulation of RPL34, which interacts with the subunits of eukaryotic translation initiation factor 3 (eIF3) and probably involves the translational control of growth-promoting proteins. Our findings suggest that RPL34 plays an important role in the proliferation of osteosarcoma cells.

No MeSH data available.


Survival analysis of 95 OS patients.Kaplan-Meter survival curves represent the overall survival for OS patients in the two groups, indicating that the overall 3-year survival rate of the OS patients with high RPL34 expression is significantly lower than those with low RPL34 expression, **P = 0.004.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC5121591&req=5

f3: Survival analysis of 95 OS patients.Kaplan-Meter survival curves represent the overall survival for OS patients in the two groups, indicating that the overall 3-year survival rate of the OS patients with high RPL34 expression is significantly lower than those with low RPL34 expression, **P = 0.004.

Mentions: All 95 patients with OS were regularly followed-up in the long term. Kaplan-Meier survival curve was created to describe the overall survival for the patients with OS. A significant difference of the overall 3-year survival rate was observed between the high-expression RPL34 patients with immunoreactive scores >7.1 (35.42%, 17/48) and the low-expression RPL34 patients with immunoreactive scores ≤7.1 (61.70%, 29/47) by log-rank test (Fig. 3, P = 0.004). The data indicated that high-level expression of RPL34 in patients with OS predicts a worse prognosis.


Highly expressed ribosomal protein L34 indicates poor prognosis in osteosarcoma and its knockdown suppresses osteosarcoma proliferation probably through translational control
Survival analysis of 95 OS patients.Kaplan-Meter survival curves represent the overall survival for OS patients in the two groups, indicating that the overall 3-year survival rate of the OS patients with high RPL34 expression is significantly lower than those with low RPL34 expression, **P = 0.004.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC5121591&req=5

f3: Survival analysis of 95 OS patients.Kaplan-Meter survival curves represent the overall survival for OS patients in the two groups, indicating that the overall 3-year survival rate of the OS patients with high RPL34 expression is significantly lower than those with low RPL34 expression, **P = 0.004.
Mentions: All 95 patients with OS were regularly followed-up in the long term. Kaplan-Meier survival curve was created to describe the overall survival for the patients with OS. A significant difference of the overall 3-year survival rate was observed between the high-expression RPL34 patients with immunoreactive scores >7.1 (35.42%, 17/48) and the low-expression RPL34 patients with immunoreactive scores ≤7.1 (61.70%, 29/47) by log-rank test (Fig. 3, P = 0.004). The data indicated that high-level expression of RPL34 in patients with OS predicts a worse prognosis.

View Article: PubMed Central - PubMed

ABSTRACT

Osteosarcoma has devastating health implications on children and adolescents. However, due to its low incidence and high tumor heterogeneity, it is hard to achieve any further improvements in therapy and overall survival. Ribosomal protein L34 (RPL34) has been increasingly recognized to promote the proliferation of malignant cells, but its role in osteosarcoma has not been investigated. In this study, real-time quantitative PCR (RT-qPCR) and immunohistochemistry revealed that RPL34 was highly expressed in osteosarcoma tissues when compared to adjacent tissues and normal bone tissues. Survival analysis showed that high expression of RPL34 predicted a poor prognosis for osteosarcoma patients. Knockdown of RPL34 in Saos-2 cells via lentivirus-mediated small interfering RNA (siRNA) significantly inhibited cell proliferation, induced cell apoptosis and G2/M phase arrest. Moreover, screening of transcription factors using University of California Santa Cruz (UCSC) Genome Browser, protein-protein interaction (PPI) network analysis, Gene Ontology (GO) and pathway enrichment analysis revealed that MYC participates in the transcriptional regulation of RPL34, which interacts with the subunits of eukaryotic translation initiation factor 3 (eIF3) and probably involves the translational control of growth-promoting proteins. Our findings suggest that RPL34 plays an important role in the proliferation of osteosarcoma cells.

No MeSH data available.